Basel, Switzerland, 22 October 2009 – Evolva SA, a Swiss headquartered international biotech company today announced a CHF 28 million first closing of its Series B financing round. The Series B financing is led by current investor Aravis and new investors Auriga Partners, Vinci Capital – Renaissance PME and Wellington Partners. BioMedInvest and an undisclosed private investor participated as co-investors in the first closing, as well as Evolva's existing investors Astellas Venture, Dansk Innovation, Novartis Bioventures and Sunstone Capital.
